British journal of haematology
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Exanthema; Female; Fenretinide; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab
Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma (B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a phase I-II study of fenretinide with rituximab for B-NHLs. Eligible diagnoses included indolent B-NHL or mantle cell lymphoma. The phase I design de-escalated from fenretinide at 900 mg/m
Cowan, Andrew J; Stevenson, Phillip A; Gooley, Ted A; Frayo, Shani L; Oliveira, George R; Smith, Stephen D; Green, Damian J; Roden, Jennifer E; Pagel, John M; Wood, Brent L; Press, Oliver W; and Gopal, Ajay K, "Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma." (2017). Articles, Abstracts, and Reports. 2360.